How to appeal a Humana plaque psoriasis + psoriatic arthritis denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for plaque psoriasis + psoriatic arthritis

Cited policy: Humana Vtama (Tapinarof 1% Cream) PA

Plaque psoriasis, FDA-approved indication. Adults May 2022; ages 2+ Dec 2024. No BSA cutoff. Trial + failure / intolerance of topical corticosteroid OR sensitive-site (face / genital / fold) avoidance of chronic steroids. 30-tube limit per 30 days.

How Humana denies plaque psoriasis + psoriatic arthritis — and how to counter it

Where Humana pushes back: 1) 'Experimental — use clobetasol first'; 2) Cost-tier exclusion; 3) Pediatric coverage gap.

Counter-arguments that hold up: Vtama (tapinarof 1% cream) FDA-approved May 23, 2022 plaque adults; Dec 16, 2024 expansion to ages 2+. PSOARING-1 + PSOARING-2 (Lebwohl NEJM 2021;385:2219-2229) Phase 3 — PGA 0/1 36-40% wk 12. AhR-agonist mechanism — non-steroid, safe for sensitive sites (face / genital / intertriginous) where chronic potent steroid causes atrophy / striae / TSWS / HPA-axis suppression. AAD-NPF 2021 topical guideline + AAD 2024 update endorse non-steroid topicals for sensitive sites. Maintenance use without rebound (PSOARING-3 LTE).

What Humana typically denies for plaque psoriasis + psoriatic arthritis

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For plaque psoriasis + psoriatic arthritis, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the plaque psoriasis + psoriatic arthritis treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira
• Enbrel
• Remicade
• Cimzia
• Simponi
• Cosentyx

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.